Acromegaly Treatment Quality of Life Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

126 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2016-12-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that treatment of acromegaly will be associated with an improvement in quality of life compared to active acromegaly. At the same time, they will also be studying the effects of different acromegaly treatments on the quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment

NCT01302652

Acromegaly

COMPLETED

Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency

NCT00182091

Acromegaly Growth Hormone Deficiency Pituitary Disease

COMPLETED NA

Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?

NCT02152124

Acromegaly

COMPLETED

Acromegaly Combination Treatment Study

NCT01538966

Acromegaly

TERMINATED NA

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

NCT00376064

Acromegaly

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acromegaly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acomegaly with Pegvisomant

Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.

No interventions assigned to this group

Acromegaly with somatostatin analog

Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly

No interventions assigned to this group

Active Acromegaly

Patients not on drugs for treatment of acromegaly

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-90
* Active acromegaly or receiving pegvisomant monotherapy or receiving somatostatin analog monotherapy

Exclusion Criteria

* Untreated thyroid or adrenal insufficiency. Subjects on replacement therapy must be stable for at least 3 months prior to entry into the study
* Initiation or discontinuation of testosterone or estrogen within 3 months of entry
* Pregnant and nursing women

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No